JP2021517826A5 - - Google Patents
Info
- Publication number
- JP2021517826A5 JP2021517826A5 JP2020568663A JP2020568663A JP2021517826A5 JP 2021517826 A5 JP2021517826 A5 JP 2021517826A5 JP 2020568663 A JP2020568663 A JP 2020568663A JP 2020568663 A JP2020568663 A JP 2020568663A JP 2021517826 A5 JP2021517826 A5 JP 2021517826A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide according
- oligonucleotide
- nucleotides
- antisense
- length
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637574P | 2018-03-02 | 2018-03-02 | |
| US62/637,574 | 2018-03-02 | ||
| PCT/US2019/018189 WO2019168687A1 (en) | 2018-03-02 | 2019-02-15 | Compositions and methods for inhibiting gys2 expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517826A JP2021517826A (ja) | 2021-07-29 |
| JP2021517826A5 true JP2021517826A5 (enExample) | 2022-02-24 |
| JP7453921B2 JP7453921B2 (ja) | 2024-03-21 |
Family
ID=67805080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568663A Active JP7453921B2 (ja) | 2018-03-02 | 2019-02-15 | Ｇｙｓ２発現を阻害するための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11572562B2 (enExample) |
| EP (1) | EP3740247A4 (enExample) |
| JP (1) | JP7453921B2 (enExample) |
| KR (1) | KR102804353B1 (enExample) |
| CN (1) | CN112055598B (enExample) |
| AU (1) | AU2019227510B2 (enExample) |
| CA (1) | CA3092092A1 (enExample) |
| IL (2) | IL325191A (enExample) |
| MX (1) | MX2020009072A (enExample) |
| WO (1) | WO2019168687A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3092092A1 (en) | 2018-03-02 | 2019-09-06 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gys2 expression |
| AU2020268798A1 (en) * | 2019-05-03 | 2021-11-04 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules with shortened sense strands |
| WO2022223515A2 (en) * | 2021-04-19 | 2022-10-27 | Novo Nordisk A/S | Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression |
| AU2024269205A1 (en) * | 2023-05-11 | 2025-12-11 | Keymed Biosciences (Us) Inc. | Dsrna molecules for regulating masp2 gene activity |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030004122A1 (en) | 1997-11-05 | 2003-01-02 | Leonid Beigelman | Nucleotide triphosphates and their incorporation into oligonucleotides |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| US20050119210A1 (en) * | 2003-05-20 | 2005-06-02 | Xiaobing Be | Compositions and methods for diagnosing and treating cancers |
| US20060078902A1 (en) * | 2004-04-15 | 2006-04-13 | Michaeline Bunting | Method and compositions for RNA interference |
| WO2005116204A1 (ja) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| EP2285385A4 (en) * | 2008-04-15 | 2013-01-16 | Quark Pharmaceuticals Inc | COMPOUNDS BASED ON RNSI TO INHIBIT NRF2 |
| DK2341943T3 (en) | 2008-09-22 | 2019-02-25 | Dicerna Pharmaceuticals Inc | COMPOSITIONS AND METHODS OF SPECIFIC INHIBITION OF DSRNA REPRINT WITH MODIFICATIONS |
| KR101728655B1 (ko) * | 2008-12-18 | 2017-04-19 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| WO2010105372A1 (en) * | 2009-03-20 | 2010-09-23 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis c virus expression |
| JP2014530602A (ja) | 2011-10-05 | 2014-11-20 | プロティバ バイオセラピューティクス インコーポレイテッド | アルデヒドデヒドロゲナーゼをサイレンシングするための組成物および方法 |
| AU2015330670B2 (en) * | 2014-10-10 | 2022-01-06 | Novo Nordisk Health Care Ag | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
| DK3569711T3 (da) | 2014-12-15 | 2021-02-22 | Dicerna Pharmaceuticals Inc | Ligandmodificerede dobbeltstrengede nukleinsyrer |
| US10689647B2 (en) | 2015-05-08 | 2020-06-23 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA |
| EP3416689B1 (en) | 2016-02-18 | 2023-01-18 | CRISPR Therapeutics AG | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
| US11597926B2 (en) * | 2017-12-22 | 2023-03-07 | Roche Innovation Center Copenhagen A/S | Thiophosphoramidites |
| CA3092092A1 (en) | 2018-03-02 | 2019-09-06 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gys2 expression |
-
2019
- 2019-02-15 CA CA3092092A patent/CA3092092A1/en active Pending
- 2019-02-15 AU AU2019227510A patent/AU2019227510B2/en active Active
- 2019-02-15 CN CN201980029587.XA patent/CN112055598B/zh active Active
- 2019-02-15 IL IL325191A patent/IL325191A/en unknown
- 2019-02-15 JP JP2020568663A patent/JP7453921B2/ja active Active
- 2019-02-15 US US16/977,152 patent/US11572562B2/en active Active
- 2019-02-15 MX MX2020009072A patent/MX2020009072A/es unknown
- 2019-02-15 EP EP19760244.4A patent/EP3740247A4/en active Pending
- 2019-02-15 KR KR1020207027734A patent/KR102804353B1/ko active Active
- 2019-02-15 WO PCT/US2019/018189 patent/WO2019168687A1/en not_active Ceased
-
2020
- 2020-08-31 IL IL277058A patent/IL277058A/en unknown
-
2023
- 2023-01-18 US US18/156,177 patent/US12534730B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521796A5 (enExample) | ||
| JP2021517826A5 (enExample) | ||
| JP2021511042A5 (enExample) | ||
| CN113994000A (zh) | 包括胞苷类似物的反义rna编辑寡核苷酸 | |
| JP2021006029A5 (enExample) | ||
| JP2020529197A5 (enExample) | ||
| JP2020188756A5 (enExample) | ||
| JP2019214587A5 (enExample) | ||
| JP2023536974A5 (enExample) | ||
| JP2018150344A5 (enExample) | ||
| JP7258773B2 (ja) | α－１アンチトリプシン（ＡＡＴ）ＲＮＡｉ剤、ＡＡＴ ＲＮＡｉ剤を含む組成物、及び使用方法。 | |
| JP2020500929A5 (enExample) | ||
| JP2024056842A5 (enExample) | ||
| JP2022553348A5 (enExample) | ||
| Gryaznov | Oligonucleotide N3′→ P5′ Phosphoramidates and Thio‐Phoshoramidates as Potential Therapeutic Agents | |
| JP2011505833A5 (enExample) | ||
| JP2016530882A5 (enExample) | ||
| JP2021507686A5 (enExample) | ||
| TW201726918A (zh) | 抑制lpa之基因表現之組合物及方法 | |
| JP2023518409A5 (enExample) | ||
| JP2018516091A5 (enExample) | ||
| JP2008523157A5 (enExample) | ||
| JP2003520811A5 (enExample) | ||
| JP2023538284A5 (enExample) | ||
| JP2007529224A5 (enExample) |